Life Science Connect Blog

31. FDA News Roundup: AstraZeneca, Teva, Amgen, And More 4/2/2015

    What regulatory decisions did you miss this week?

32. What Is The Reason For Uneven Gender Roles In Pharma Leadership? 3/27/2015

    About a month ago, Sanofi put an end to its several-month-long search for a new CEO by selecting Bayer’s Olivier Brandicourt. The day the company announced this move, I published a blog questioning why it’s so often expected that CEO positions in pharma (and really in any industry) will most likely be held by men. This question arose after finding a survey that revealed a majority of respondents believed the position would be taken by a male.

33. FDA News Roundup: Merck, Actavis, Vertex, And More 3/20/2015

    What FDA decisions did you miss this week?
     

34. Can These 3 Anti-Counterfeiting Methods Protect Pharma's Supply Chain? 3/13/2015

    The Drug Quality and Security Act (DQSA) is on the minds of many these days as companies make the necessary investments and launch initiatives to ensure regulatory compliance and supply chain integrity. However, I’ve also been taking note of some of the ways companies and researchers in the industry have been trying to protect pharma products from counterfeiters and keep patients from being fooled by counterfeiters’ increasingly sophisticated tricks.

35. FDA News Roundup: Bristol-Myers Squibb, Bayer, Astellas, And More 3/11/2015

    What FDA decisions have you missed in the last week?

36. FDA News Roundup: Shire, Bristol-Myers Squibb, Alexion, And More 3/6/2015

    What FDA decisions did you miss this week?

37. Will 2015 Be The Year Of Drug Pricing Transparency? 3/6/2015

    Lately, the pharma industry has been facing a large amount of resistance to its own price tags. In the past year, we’ve been greeted by headlines about drugs launching with $90-, $100-, and even $140,000-per-patient treatment regimens.  But we’ve also been greeted with reports about the high cost of development—a $2.6 billion endeavor, Tufts Center for the Study of Drug Development reported last fall.

38. FDA News Roundup: Pfizer, Novartis, Sanofi, and More 3/2/2015

    What drug approvals have you missed recently?

39. How To Snag A Drug R&D Partner: 3 Takeaways From Merck's Latest Deal 2/27/2015

    It’s been a week of high-profile acquisitions. We saw Bristol-Myers Squibb snap up Flexus Biosciences for its immunotherapy programs. Shire bought Meritage Pharma. After the Allergan flop, Valeant finally got Salix Pharma to go steady, and Ipsen shelled out 6 million euros to buy U.K.-based biotech Canbex. But arguably more attention was placed on one $450 million collaboration than on the billions spent in this latest batch of acquisitions.

40. Poll Expected Sanofi CEO To Be Male: What's Up With That? 2/20/2015

    I’m interested in the topic of gender in any industry, and this week, a headline in BioSpace caught my eye: “Poll Finds Massive Support for French, Male CEO at Sanofi.” According to this survey, 86 percent of responders (353 people) believed the new CEO would be male. Turns out, these responders were right: Soon-to-be-former Bayer CEO, Olivier Brandicourt, will be taking over as Sanofi CEO on April 2.